Skip to main content
TARS logo

TARS · Tarsus Pharmaceuticals, Inc. · Documents

Track TARS — free
$78.20 -0.48 (-0.61%) At close · Nov 17 Play latest call Q3 2026 earnings call transcript
Market Cap
$3.86B
Shares
49.31M
Volume · Nov 17 542.25K Avg daily vol (3M) 874.8K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $451.36M up 146.7% 10-K filed Feb 23, 2026 Quarterly report FY2026 Q3 Revenue $194.57M up 63.9% 10-Q filed Nov 3, 2026 Latest results XDEMVY sales rise 64% to $194.6 million in third quarter 8-K filed Nov 3, 2026 Earnings call Q3 2026 earnings call Held Nov 3, 2026
2026
Nov 3
Earnings call
Quarterly sales hit $194.6 million as 2026 outlook rises

Tarsus reported Q3 XTENVI net product sales of $194.6 million and raised full-year 2026 sales guidance to $715 million to $730 million. DTC spending will increase to approximately $95 million.

5 source passages
Xtempi's continued growth is giving us greater opportunities to invest in Tarsus' future. One, increasing demand as more patients recognize their symptoms and ask about XTENVI. Starting with our third quarter results, we delivered Xtembe net product sales of $194.6 million, driven by strong prescription volumes, gross margin of approximately 93%, and we ended the quarter with cash and cash equivalents of approximately $310 million. Now, turning to our updated full-year 2026 guidance, we expect our full-year 2026 Extenvy sales outlook to be between $715 million to $730 million. That's why we're adding $5 million to our DTC spend, bringing our full-year investment to approximately $95 million Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
XDEMVY sales rise 64% as net loss reaches $668.3 million

Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.

Revenue $194.57M ▲ 63.9% Net loss $668.33M Diluted EPS -$14.40
Read from the MD&A section
3 source passages
Generated $194.6 million of net product sales of XDEMVY in the U.S. in the third quarter of 2026, a year-over-year increase of approximately 64%. Our net losses were $668.3 million and $12.6 million for the three months ended September 30, 2026 and 2025, respectively Acquired in-process research and development expense (“IPR&D”) was $632.2 million for the three months ended September 30, 2026 Open the document at this passage
Nov 3
Current report 8-K
XDEMVY sales rise 64% to $194.6 million in third quarter

Tarsus reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64% year-over-year. Net loss widened to $668.3 million, driven by $632.2 million of acquired in-process R&D from the iRenix and Alkeus acquisitions. Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.

Financial results
4 source passages
XDEMVY generated third quarter 2026 net product sales of $194.6 million, a year-over-year increase of approximately 64%. Net loss: was $668.3 million, compared to $12.6 million for the same period in 2025. were $632.2 million for the period, consisting of $81.0 million related to the acquisition of iRenix and $551.2 million related to the acquisition of Alkeus As of September 30, 2026, cash, cash equivalents and marketable securities were $309.6 million. Open the document at this passage
Oct 13
Registration statement S-3ASR
Registration statement

Tarsus Pharmaceuticals, Inc. registered up to 2,908,692 shares of common stock for resale by selling stockholders; it will receive no proceeds from their sales.

Read from the first part of this long document
Oct 13
Registration statement S-3ASR
Registration statement

Tarsus Pharmaceuticals, Inc. registered up to 2,232,144 shares of common stock for resale by selling stockholders, comprising 2,098,519 shares and 133,625 shares issuable upon exercise of pre-funded warrants. The company will receive no proceeds from share sales.

Read from the first part of this long document
Oct 13
Current report 8-K/A Events of Sep 4
Current report

Tarsus Pharmaceuticals reported completion of its Alkeus Pharmaceuticals acquisition on September 10, 2026. Alkeus had an accumulated deficit of $74.3 million at September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Read from the first part of this long document
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $173.91M ▲ 69.4% Net loss $18.55M Diluted EPS -$0.43
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $162.05M ▲ 106.9% Net loss $6.97M Diluted EPS -$0.16
Apr 28
Proxy statement DEF 14A Meeting Jun 25, 2026
Proxy statement AI summary on its way
Feb 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $451.36M ▲ 146.7% Net loss $66.42M Diluted EPS -$1.59
2025
Showing 1–50 of 141 documents
Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 263 filings 247 filers Visit website Investor relations